APP and Alzheimer disease: Analyzing the three drugs more closely, the therapeutic effects of Deferoxamine are promising in the treatment of AD; this compound seems to act especially on extracellular iron [212] in a 1:1 ratio [213, 214] and can modulate the expression of different genes (hypoxia-inducing factor, IRP-1, and APP) with a blocking effect on ROS production [215].